A Study to Evaluate the Whitening Effect of Mineral Sunscreens in Multi-Cultural Skin Tones

Sponsor
Johnson & Johnson Consumer Inc. (J&JCI) (Industry)
Overall Status
Completed
CT.gov ID
NCT05565625
Collaborator
(none)
97
1
1
3
32.4

Study Details

Study Description

Brief Summary

The purpose of this study is to evaluate the whitening potential effect of different mineral sunscreens across multi-cultural skin tones through instrumentation, imaging, and self-assessment and also evaluate the relationship between self-perception and objective measurement of whitening.

Condition or Disease Intervention/Treatment Phase
  • Other: Sunscreen A
  • Other: Sunscreen B
  • Other: Sunscreen C
  • Other: Sunscreen D
  • Other: Sunscreen E
  • Other: Sunscreen F
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
97 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Basic Science
Official Title:
A Single-Center, Clinical Study to Evaluate the Whitening Effect of Mineral Sunscreens in Multi-Cultural Skin Tones Thru Instrumentation Measurements, Imaging, and Self-Assessments
Actual Study Start Date :
Dec 29, 2021
Actual Primary Completion Date :
Mar 30, 2022
Actual Study Completion Date :
Mar 30, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Sunscreen

Participants will receive two of six sunscreens (A, B, C, D, E, and F) at Visit 1 (Day 1) to apply to whole lower legs (1 sunscreen per lower leg), between the knee and ankle. Participant will then select one of the two sunscreens randomly assigned to lower legs and apply the selected sunscreen to full face. After lower legs and facial applications are completed, a trained designee will delineate six 4 centimeters (cm)*4 cm test sites on the participants' volar forearms (3 test sites per volar forearm). The six sunscreens will be randomly assigned to the six test sites at a dose of 2.00 +- 0.05 milligrams per centimeter square (mg/cm^2) using a 1cc tuberculin syringe (without a needle) and a clean finger cot for approximately 20 to 50 seconds and applied by a trained designee.

Other: Sunscreen A
Participants will topically apply Sunscreen A at Visit 1.

Other: Sunscreen B
Participants will apply Sunscreen B at Visit 1.

Other: Sunscreen C
Participants will apply Sunscreen C at Visit 1.

Other: Sunscreen D
Participants will apply Sunscreen D at Visit 1.

Other: Sunscreen E
Participants will apply Sunscreen E at Visit 1.

Other: Sunscreen F
Participants will apply Sunscreen F at Visit 1.

Outcome Measures

Primary Outcome Measures

  1. Whitening Potential of Mineral Sunscreens Across Multi-cultural Skin Tones Through Instrumentation [Visit 1 (Day 1)]

    Whitening potential of mineral sunscreens across multi-cultural skin tones through instrumentation (SkinSkan measurements) will be reported. SkinSkan is a non-invasive diagnostic tool that uses an optical fiber probe to collect the fluorescence signal from skin after excitation light is delivered through the same fiber probe.

  2. Whitening Potential of Mineral Sunscreens Across Multi-cultural Skin Tones Through Imaging [Visit 1 (Day 1)]

    Whitening potential of mineral sunscreens across multi-cultural skin tones through imaging (facial and vocal forearms) will be reported. Image analysis will be done by using the Matlab software. A small region of interest (ROI) will be defined on the gray standard, and five regions on the face (forehead, nose, chin, left cheek, and right cheek) and the test regions on the volar forearms. The average RGB (red, green, and blue) values from these ROI will be extracted from the images. The RGB values from the gray standard will be used to calculate the correction factors per image based on the gray standard's target RGB values. Matlab will be used to convert the corrected RGB values to the LAB values. Skin whitening defined as the change in L* values pre and post product application. L* value is defined as lightness in LAB color space. High L* value corresponds to whiter color while low L* value corresponds to blacker color.

  3. Whitening Potential of Mineral Sunscreens Across Multi-cultural Skin Tones Through Self-assessment [Visit 1 (Day 1)]

    Whitening potential of mineral sunscreens across multi-cultural skin tones through self-assessment will be reported via self-assessment questionnaire (Part B). This questionnaire rank whitening potential after application of the sunscreen product to the designated test areas on both inner forearms in order of least whitening (1) to most whitening (6).

  4. Relationship Between Self-assessment and Instrumentation [Visit 1 (Day 1)]

    Relationship between self-assessment and instrumentation (sunscreen product) will be reported via self-assessment questionnaire (Part A) which include the question about 'how much did you like or dislike the appearance of the sunscreen product on your skin' rated on a 5-point likert scale where 1 indicates "disliked it very much", 2 indicates "disliked it somewhat", 3 indicates "neither liked or disliked it", 4 indicates "liked it somewhat" and 5 indicates "liked it very much".

Secondary Outcome Measures

  1. Rate of Usage Versus Whitening Effect from a Sunscreen [Visit 1 (Day 1)]

    Whitening effect from a sunscreen that impacts participant application behavior and ultimately their sun protection will be reported. This is being determined by correlation of the self-application dosage (milligrams per centimeter square [mg/cm^2]) per treatment area versus measured whitening effect (delta L*).

  2. Skin Reflectance Before and After Sunscreen Applications as Assessed by SkinSkan Instrument [Visit 1 (Day 1)]

    Skin reflectance will be assessed by SkinSkan instrument. SkinSkan instrument is a non-invasive diagnostic tool that uses an optical fiber probe to collect the signal from skin after excitation light is delivered through the same fiber probe. The spectra acquired at post sunscreen application and baseline for each site will be used to calculate Sun Protection Factor (SPF) following published Hybrid Diffuse Reflectance Spectroscopy (HDRS) method. Four replicates of spectra will be averaged to produce mean intensity of reflectance at baseline and sunscreen covered skin. Thus, each site measurement will produce one SPF level.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 55 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Self-reported natural skin tone/skin color, targeting the following: skin tones "Pale/fair to light white" and "White to light beige" (n = 30 participants), skin tones "Beige to light tan/light olive" and "Medium tan/medium olive to light brown" (n = 30 participants), and Skin tones "Medium brown to dark brown" and "darkest brown to darkest black" (n = 30 participants)

  • Has a history of using or is a current user of sunscreens

  • Generally, in good health based on medical history reported by the participants

  • Able to read, write, speak, and understand English

  • Individual has signed the consent for photograph release and informed consent document (ICD) including Health Insurance Portability and Accountability Act (HIPAA) disclosure

  • Intends to complete the study and is willing and able to follow all study instructions

Exclusion Criteria:
  • Has known allergies or adverse reactions to common topical skincare products or ingredients in the ISMs

  • Presents with a skin condition on the face, volar forearms, or lower legs that may confound the study results (example, psoriasis, eczema, atopic dermatitis, cutaneous xerosis, erythema, or active skin cancer) or interfere with evaluations (example, excessive hair, tattoos, scarring, very uneven skin tone, sunburn, scratches/broken/compromised skin)

  • Has shaved or used any hair removal method on lower legs or volar forearms within 24 hours of Visit 1

  • Has a history of a confirmed or suspected coronavirus disease 2019 (COVID-19) infection within 30 days prior to the study visit

  • Within 14 days prior to Visit 1, has been in close contact (exposure within 6 feet for a cumulative time of 15 minutes or more over a 24-hour period) with anyone who has been infected with COVID-19

  • Is under a COVID-19 isolation/quarantine order

  • Has experienced any of the following self-reported symptoms of COVID-19 within 2 weeks prior to the study visit: unexplained cough, shortness of breath/difficulty breathing, fatigue, body aches (headaches, muscle pain, stomachaches), conjunctivitis, loss of smell, loss of taste, poor appetite, nausea, vomiting, diarrhea, palpitations, or chest pain/tightness; temperature greater than or equal to (>=) 37.5 degrees celsius (C)/99.5 degrees fahrenheit (F), measured; use of fever or pain reducers within 2 days prior to the study visit

  • Has self-reported Type 1 or Type 2 diabetes or is taking insulin or another anti-diabetic medication

  • Is taking a medication that would mask an adverse event (AE) or confound the study results, including: Immunosuppressive or steroidal drugs within 2 months before Visit 1; non-steroidal anti-inflammatory drugs within 5 days before Visit 1; antihistamines within 1 week before Visit 1

  • Is self-reported to be pregnant or planning to become pregnant during the study

  • Has a history of or a concurrent health/other condition/situation which may put the individual at significant risk, confound the study results, or interfere significantly with the individual's participation in the study

  • Is simultaneously participating in any other clinical study or has participated in any product-use study within 14 days prior to Visit 1

  • Is an employee/contractor or immediate family member of the principle investigator (PI), study site, or sponsor

Contacts and Locations

Locations

Site City State Country Postal Code
1 Validated Claim Support (VCS) Teaneck New Jersey United States 07666

Sponsors and Collaborators

  • Johnson & Johnson Consumer Inc. (J&JCI)

Investigators

  • Principal Investigator: David Wrone, M.D., FAAD, Validated Claim Support (VCS)

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Johnson & Johnson Consumer Inc. (J&JCI)
ClinicalTrials.gov Identifier:
NCT05565625
Other Study ID Numbers:
  • CCSSKA004479
  • CCSSKA004479
First Posted:
Oct 4, 2022
Last Update Posted:
Oct 4, 2022
Last Verified:
Sep 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 4, 2022